Overview
The study population consists of approximately 40 adult outpatients aged 40 years or older with symptomatic hip osteoarthritis of at least 1 year of clinical evolution, treated with intra-articular hyaluronic acid in routine clinical practice within the Traumatology and Rehabilitation departments of participating hospitals in Spain.
Eligibility
Inclusion Criteria:
- Age: \>40 years at the time of study inclusion
- Preserved gait capability, with or without assistive devices
- Symptomatic hip arthropathy with a disease evolution of at least 1 year.
- Radiographic Kellgren-Lawrence grade II-III documented within the 12 months prior to study entry
- Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score \>15
- Patient currently receiving intra-articular hyaluronic acid treatment within 3 months prior to study inclusion
Exclusion Criteria:
- Refusal to provide written informed consent
- Females who are pregnant, breastfeeding, or not using effective contraception
- Body Mass Index (BMI) ≥ 30 kg/m²
- Presence of other chronic or autoimmune diseases that could interfere with clinical evaluation
- History of hypersensitivity or allergy to hyaluronic acid or its derivatives
- Prior administration of intra-articular platelet-rich plasma (PRP) or intra-articular corticosteroids within 3 months, or intra-articular hyaluronic acid within 6 months prior to study entry
